You have 9 free searches left this month | for more free features.

RIC (reduced-intensity conditioning)

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies Trial in Philadelphia (RIC: Distal Campath, RIC:Intermediate

Recruiting
  • Non Malignant Diseases
  • +2 more
  • RIC: Distal Campath
  • +2 more
  • Philadelphia, Pennsylvania
    The Children's Hospital of Philadelphia
Mar 8, 2022

Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplant (HSCT) Trial in Pittsburgh

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • +2 more
  • Reduced-Intensity Conditioning Regimen
  • Myeloablative Conditioning Regimen
  • Pittsburgh, Pennsylvania
    UPMC Children's Hospital of Pittsburgh
Jan 4, 2023

Hematologic Malignancies Trial in Minneapolis (Haplo HCT <55 years old, Haplo HCT =55 years old, GVHD Prophylaxis)

Recruiting
  • Hematologic Malignancies
  • Haplo HCT <55 years old
  • +4 more
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Jan 25, 2023

Leukemia, Myeloid, Acute, MDS, Hematopoietic Stem Cell Transplantation Trial in Shanghai (Venetoclax plus RIC)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • +3 more
  • Venetoclax plus RIC
  • Shanghai, Shanghai, China
    Shanghai General Hospital
Oct 12, 2022

Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders Trial in Minneapolis (Blood and Marrow Transplant)

Recruiting
  • Sickle Cell Disease
  • +4 more
  • Blood and Marrow Transplant
  • Minneapolis, Minnesota
    Masonic Caner Center at University of Minnesota
May 23, 2022

Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in Minneapolis (N-803)

Completed
  • Acute Myelogenous Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Jan 4, 2023

Hematologic Disorders, Hemoglobinopathies, Immunodeficiencies Trial in Minneapolis (drug, radiation, biological)

Recruiting
  • Hematologic Disorders
  • +2 more
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Jul 12, 2021

Chronic Lymphocytic Leukemia Trial in Spain (Ofatumumab)

Completed
  • Chronic Lymphocytic Leukemia
  • Badalona, Spain
  • +8 more
May 2, 2022

Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders Trial in New Haven, Saint Louis (RIC regimen,

Recruiting
  • Severe Sickle Cell Disease
  • +5 more
  • RIC regimen
  • GVHD prophylaxis regimen
  • New Haven, Connecticut
  • +1 more
Feb 4, 2022

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia Trial in Minneapolis (biological, drug,

Not yet recruiting
  • Acute Myelogenous Leukemia
  • +17 more
  • Peripheral Blood Stem Cell Transplant
  • +7 more
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Mar 27, 2023

Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

Recruiting
  • Primary Immunodeficiency (PID)
  • +4 more
  • data collection
  • Pittsburgh, Pennsylvania
    UPMC Children's Hospital of Pittsburgh
Feb 9, 2022

Acute Myeloid Leukemia in Remission Trial in France (Fludarabine, Busulfan, ATG)

Not yet recruiting
  • Acute Myeloid Leukemia in Remission
  • Nantes, Loire Atlantique, France
  • +22 more
Jun 15, 2023

Hematologic Malignancy, Haplo-identical Stem Cell Transplantation Trial (CD45RAneg cells, prepared from mononuclear cell

Not yet recruiting
  • Hematologic Malignancy
  • Haplo-identical Stem Cell Transplantation
  • CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
  • (no location specified)
Oct 1, 2021

Graft Vs Host Disease Trial in United States (PRO 140)

Terminated
  • Graft Vs Host Disease
  • PRO 140
  • Miami, Florida
  • +7 more
Jan 13, 2022

Refractory Leukemia Trial in Shanghai (CALGE-VEN- RIC-MBF)

Recruiting
  • Refractory Leukemia
  • CALGE-VEN- RIC-MBF
  • Shanghai, Shanghai, China
  • +2 more
May 22, 2023

Epidermolysis Bullosa Trial in Aurora, Chicago, New York (Palifermin, Fludarabine, Busulfan)

Terminated
  • Epidermolysis Bullosa
  • Aurora, Colorado
  • +2 more
Aug 13, 2021

Acute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS), Allogeneic Hematopoietic Stem Cell Transplantation Trial in Wuhan

Recruiting
  • Acute Myeloid Leukemia, Adult
  • +2 more
  • Fludarabine and Busulfan
  • Fludarabine and Melphalan
  • Wuhan, Hubei, China
    Wuhan Union Hospital, Tongji Medical college, Huazhong Universit
Jan 5, 2023

Acute Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma Trial in Marseille (Hematopoietic stem cells transplantation)

Active, not recruiting
  • Acute Leukemia
  • +2 more
  • Hematopoietic stem cells transplantation
  • Marseille, France
    Institut Paoli-Calmettes
Mar 26, 2021

Acute Lymphoblastic Leukemia Trial in United Kingdom (Fludarabine, Melphalan, Alemtuzumab)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Birmingham, United Kingdom
  • +21 more
Oct 14, 2021

Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure Trial in Baltimore (Alemtuzumab, Fludarabine,

Recruiting
  • Primary Immune Deficiency Disorder
  • +2 more
  • Baltimore, Maryland
    Johns Hopkins University
Oct 20, 2022

Hematological Malignancy, Leukemia, Multiple Myeloma Trial in Milwaukee (Evomela, Fludarabine, Total Body Irradiation)

Recruiting
  • Hematological Malignancy
  • Multiple Myeloma
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Oct 4, 2022

Disease-free Survival Trial in Shanghai (MBF-RIC)

Recruiting
  • Disease-free Survival
  • Shanghai, Shanghai, China
  • +1 more
Jun 28, 2022

Hodgkin Lymphoma Trial in Valhalla (Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning)

Active, not recruiting
  • Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +2 more
  • Valhalla, New York
    New York Medical College
Oct 24, 2022

Myelofibrosis Trial in Italy (A: Fludarabine + Busulphan, B: Fludarabine + Thiotepa)

Completed
  • Myelofibrosis
  • A: Fludarabine + Busulphan
  • B: Fludarabine + Thiotepa
  • Alessandria, Italy
  • +20 more
Aug 19, 2021

Acute Leukemia, MDS Trial in Beijing (Cytarabine)

Recruiting
  • Acute Leukemia
  • Myelodysplastic Syndromes
  • Beijing, China
    Peking University, Institute of Hematolgoy
Sep 23, 2020